MorphoSys AG ("the Company" or "MorphoSys") is one of the leading antibody companies focused on the research and development of fully human antibodies. MorphoSys's proprietary state-of-the-art technologies and its over 20 years of focused antibody research and optimization expertise are successfully applied to the development of therapeutics for its commercial partners and proprietary use. The Group was founded in July 1992 as a German limited liability company. In June 1998, MorphoSys became a German stock corporation. In March 1999, the Company completed its initial public offering on Germany's "Neuer Markt": the segment of the Deutsche Börse designated for high-growth companies. On 15 January 2003, MorphoSys AG was admitted to the Prime Standard segment of the Frankfurt Stock Exchange. The registered office of the MorphoSys Group is located at Lena-Christ-Str. 48, 82152 Martinsried, Germany.
These interim consolidated financial statements were prepared in accordance with the International Financial Reporting Standards (IFRS) and the International Accounting Standards (IAS) taking into account the interpretations of the Standing Interpretations Committee (SIC) and the International Financial Reporting Interpretations Committee (IFRIC) as applied by the European Union. These interim consolidated financial statements are in compliance with IAS 34 "Interim Financial Reporting".
The condensed interim consolidated financial statements do not contain all of the information and disclosures required for consolidated financial statements at the end of the financial year and therefore should be read in conjunction with the consolidated financial statements dated 31 December 2013.
The condensed interim consolidated financial statements were approved for publication on 7 November 2014.
The consolidated financial statements as of 30 September 2014 comprise MorphoSys AG, Sloning BioTechnology GmbH, and Poole Real Estate Ltd. (formerly Biogenesis UK Ltd.), collectively as the "Group".
Upon entry in the commercial register on 13 August 2014 and based on the merger agreement dated 27 June 2014, MorphoSys IP GmbH, as the transferring legal entity, was merged into MorphoSys AG, as the acquiring legal entity, with the effective date of 1 January 2014.
MorphoSys USA, Inc. was liquidated as of 30 September 2014. The remaining assets were distributed to MorphoSys AG as the sole shareholder.
On 30 September 2014, Poole Real Estate Ltd. was in the process of liquidation. The liquidation was resolved by the shareholders and entered into the commercial register of the United Kingdom (Companies House) on 20 March 2014.